Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuroPaceNPCE +0.55%69 3-Year EPS without NRI Growth Rate is 29.80% as of Jun. 2026, which is 45% above its 10-year median of 20.60. GuruFocus rates NPCE with a GF Score™ of 69/100 and a GF Value™ of $12.59 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 658 Medical Devices & Instruments companies, NeuroPace ranks better than 77.2% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 29.80% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 22.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 7 years, the highest 3-Year average EPS without NRI Growth Rate of NeuroPace was 29.80% per year. The lowest was 10.90% per year. And the median was 20.60% per year.
NeuroPace (NAS:NPCE) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
NeuroPace 3-Year EPS without NRI Growth Rate Related Terms
NPCE vs SENS, CLPT, SGHT: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, NeuroPace's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroPace 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where NeuroPace's 3-Year EPS without NRI Growth Rate falls into.
NeuroPace 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 29.80% mean?
NeuroPace (NPCE) has a 3-Year EPS without NRI Growth Rate of 29.80% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for NeuroPace and its competitors. This is 45% above median its historical median of 20.60. Over the past decade, NeuroPace's 3-Year EPS without NRI Growth Rate has ranged from 10.90 to 29.80. According to the industry distribution chart, NeuroPace ranks #150 out of 658 companies in the Medical Devices & Instruments industry, placing it in the top 22.8%.
Is NeuroPace's 3-Year EPS without NRI Growth Rate too high?
NeuroPace's current 3-Year EPS without NRI Growth Rate of 29.80% is 45% above median its 10-year median of 20.60. Over the past 10 years, this metric has ranged from a low of 10.90 to a high of 29.80. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 7.90. NeuroPace's value of 29.80% is 277.2% above this industry median. Based on the distribution chart, NeuroPace ranks #150 out of 658 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, NeuroPace has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuroPace's 3-Year EPS without NRI Growth Rate compare to SENS and CLPT?
According to the Medical Devices & Instruments industry distribution chart, NeuroPace ranks #150 out of 658 companies for 3-Year EPS without NRI Growth Rate. This places NeuroPace in the top 23% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 7.90. NeuroPace's value of 29.80% is 277.2% above this benchmark. Historically, NeuroPace's own 3-Year EPS without NRI Growth Rate has ranged from 10.90 to 29.80 over the past decade. While the company's 10-year median is 20.60 vs. the industry median of 7.90, NeuroPace has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 7.90, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuroPace's current 3-Year EPS without NRI Growth Rate of 29.80% is 277.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for NeuroPace and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroPace's current 3-Year EPS without NRI Growth Rate is 29.80%, which is 45% above median its own 10-year median of 20.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroPace stock overvalued right now?
Based on GuruFocus' analysis, NeuroPace (NPCE) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.59, compared to a current price of $14.74 — trading 17.1% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 29.80%, which is 45% above median its 10-year median of 20.60 and 277.2% above the Medical Devices & Instruments industry median of 7.90. NeuroPace's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For NeuroPace (NPCE), the current 3-Year EPS without NRI Growth Rate is 29.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuroPace (NPCE) Overvalued in 2026?
Based on GuruFocus' analysis, NeuroPace stock appears to be overvalued.
The current stock price of $14.74 is trading 17.1% above its estimated GF Value™ of $12.59.
GuruFocus considers NeuroPace to be Modestly Overvalued.
Key valuation signals for NPCE:
3-Year EPS without NRI Growth Rate: 29.80% (45% above median its 10-year median of 20.60)
GF Value™: $12.59 vs. price of $14.74 (17.1% above fair value)
Industry Position: 277.2% above the Medical Devices & Instruments median (#150 of 658)
No single metric tells the full story. See the NPCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
69GF Score
Get the complete analysis for NPCE
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NPCE has been successfully added to your 
